Chiara Caparello
YOU?
Author Swipe
View article: La gestione del tumore al polmone non a piccole cellule (NSCLC) ALK positivo – l’esperienza dell’Azienda USL Toscana Nord-Ovest
La gestione del tumore al polmone non a piccole cellule (NSCLC) ALK positivo – l’esperienza dell’Azienda USL Toscana Nord-Ovest Open
View article: Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests
Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests Open
In this observational study, we described the two-month mortality among the 157 residents (age 60-100) of a nursing home after Sars-CoV-2 spreading, reporting the factors associated with the outcome. We also compared the diagnostic tests f…
View article: Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma Open
Objective: The aim of the study was to identify plasma microRNA (miRNA) biomarkers for stratifying and monitoring patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) treated with FOLFIRINOX, and to investig…
View article: Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol Open
Introduction: Although sorafenib is the upfront standard of care for advanced hepatocellular carcinoma (HCC), molecular predictors of efficacy have not been identified yet. In the ALICE-1 study, rs2010963 of VEGF-A and VEGF-C proved to be …
View article: PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC Open
This corrects the article DOI: 10.1038/bjc.2017.85.
View article: Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer Open
View article: Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer Open
View article: Oxaliplatin in pre-treated patients: maybe not the match point?
Oxaliplatin in pre-treated patients: maybe not the match point? Open
Pancreatic cancer is an aggressive disease and is projected to become one of the major causes of cancer-related death in western countries. Intensification of first-line treatment with the use of polychemotherapeutic regimens (FOLFIRINOX, …
View article: Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma
Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma Open
View article: New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Open
Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. In this review, the wide-ranging aspects of the evolution of EGFR-TKIs were collected, with a sp…
View article: PD-022 FOLFOXIRI as primary treatment for locally advanced unresectable pancreatic cancer (LAPC): a prospective study
PD-022 FOLFOXIRI as primary treatment for locally advanced unresectable pancreatic cancer (LAPC): a prospective study Open
View article: Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’
Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’ Open
View article: First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors
First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors Open
FOLFIRINOX is a standard first‐line treatment for advanced pancreatic cancer (aPC). The Gruppo Oncologico Nord Ovest (GONO) FOLFOXIRI regimen demonstrated efficacy in metastatic colorectal cancer. We aimed to evaluate activity and tolerabi…
View article: Circulating micrornas as dynamic biomarkers of disease progression during folfirinox therapy in unresectable pancreatic ductal adenocarcinoma (pdac)
Circulating micrornas as dynamic biomarkers of disease progression during folfirinox therapy in unresectable pancreatic ductal adenocarcinoma (pdac) Open
View article: FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer Open
Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOLFIRINOX is now considered a standard treatment in first-line setting, since it …
View article: Contents Vol. 91, 2016
Contents Vol. 91, 2016 Open
View article: Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data Open
View article: Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients Open
View article: Prognostic model for patients (pts) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (mFOLFIRINOX)
Prognostic model for patients (pts) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (mFOLFIRINOX) Open
View article: Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer Open
View article: Second-line chemotherapy after disease progression following first-line FOLFOXIRI in advanced pancreatic cancer patients
Second-line chemotherapy after disease progression following first-line FOLFOXIRI in advanced pancreatic cancer patients Open
View article: Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (pts) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now?
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (pts) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? Open
View article: Impact of age, ECOG PS and type of treatment on progression-free survival and overall survival in second-line therapy for advanced gastric cancer: analysis on 709 cases
Impact of age, ECOG PS and type of treatment on progression-free survival and overall survival in second-line therapy for advanced gastric cancer: analysis on 709 cases Open
View article: 2372 Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer?
2372 Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? Open
View article: P-180 Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients: a single institution retrospective cohort study
P-180 Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients: a single institution retrospective cohort study Open